文献速递淋巴瘤造血干细胞移植与细胞治疗

MATRix-RICE方案联合自体造血干细胞移植治疗继发性中枢神经系统弥漫大B细胞淋巴瘤:国际单臂2期MARIETTA试验

MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2021-01-01

该国际单臂2期试验纳入79例继发性中枢神经系统弥漫大B细胞淋巴瘤患者,给予3周期MATRix、3周期RICE后行卡莫司汀-塞替派预处理及自体HSCT。1年无进展生存率为58%(95%CI 55-61),达到主要终点;治疗相关死亡率为5%。

要点

  • MATRix-RICE联合自体HSCT在继发性中枢神经系统淋巴瘤中显示抗肿瘤活性,1年PFS率达58%。
  • 最常见3-4级毒性为血液学毒性,中性粒细胞减少61%、血小板减少60%、贫血35%。
  • 治疗相关死亡率为5%,主要死因为革兰阴性菌脓毒症。

核心结论

  • MATRix-RICE方案联合自体造血干细胞移植在该预后极差人群中具有抗肿瘤活性,且毒性可接受。

研究设计与样本

  • 国际、单臂、2期试验,在意大利、英国、荷兰和瑞士24家医院开展。
  • 纳入79例18-70岁组织学诊断的弥漫大B细胞淋巴瘤且初诊或复发时伴中枢神经系统受累、ECOG体能状态评分≤3分的成人患者。
  • 治疗方案为3周期MATRix、3周期RICE,随后卡莫司汀-塞替派预处理及自体HSCT。
  • 主要终点为1年无进展生存率,分析基于改良意向治疗人群。

主要发现

  • 79例入组,75例可评估;450个计划周期中实际完成319个(71%)。
  • 1年时42例无进展,无进展生存率58%(95%CI 55-61),达到主要终点。
  • MATRix-RICE后49例(65%;95%CI 54-76)客观缓解,其中29例(39%)完全缓解。
  • 37例缓解者接受自体HSCT;方案结束时46例(61%;95%CI 51-71)客观缓解,中位缓解持续时间26个月(IQR 16-37)。
  • 中位随访29个月(IQR 20-40),35例无进展,33例存活,2年总生存率46%(95%CI 39-53)。

关键数值与推荐

  • 3-4级毒性最常见为血液学毒性:中性粒细胞减少46/75例(61%),血小板减少45例(60%),贫血26例(35%)。

临床怎么用

  • 对于初诊或复发时伴中枢神经系统受累的弥漫大B细胞淋巴瘤成人患者,可考虑MATRix-RICE联合自体HSCT方案。
  • 治疗期间需密切监测血液学毒性及感染,尤其是革兰阴性菌脓毒症风险。

局限性

  • 单臂设计,无随机对照,结论需进一步验证。
  • 样本量有限,可评估患者75例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Secondary CNS lymphoma is a rare but potentially lethal event in patients with diffuse large B-cell lymphoma. We aimed to assess the activity and safety of an intensive, CNS-directed chemoimmunotherapy consolidated by autologous haematopoietic stem-cell transplantation (HSCT) in patients with secondary CNS lymphoma. METHODS: This international, single-arm, phase 2 trial was done in 24 hospitals in Italy, the UK, the Netherlands, and Switzerland. Adults (aged 18-70 years) with histologically diagnosed diffuse large B-cell lymphoma and CNS involvement at the time of primary diagnosis or at relapse and Eastern Cooperative Oncology Group Performance Status of 3 or less were enrolled and received three courses of MATRix (rituximab 375 mg/m2, intravenous infusion, day 0; methotrexate 3·5 g/m2, the first 0·5 g/m2 in 15 min followed by 3 g/m2 in a 3 h intravenous infusion, day 1; cytarabine 2 g/m2 every 12 h, in 1 h intravenous infusions, days 2 and 3; thiotepa 30 mg/m2, 30 min intravenous infusion, day 4) followed by three courses of RICE (rituximab 375 mg/m2, day 1; etoposide 100 mg/m2 per day in 500-1000 mL over a 60 min intravenous infusion, days 1, 2, and 3; ifosfamide 5 g/m2 in 1000 mL in a 24 h intravenous infusion with mesna support, day 2; carboplatin area under the curve of 5 in 500 mL in a 1 h intravenous infusion, day 2) and carmustine-thiotepa and autologous HSCT (carmustine 400 mg/m2 in 500 mL glucose 5% solution in a 1-2 h infusion, day -6; thiotepa 5 mg/kg in saline solution in a 2 h infusion every 12 h, days -5 and -4). The primary endpoint was progression-free survival at 1 year. Overall and complete response rates before autologous HSCT, duration of response, overall survival, and safety were the secondary endpoints. Analyses were in the modified intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02329080. The trial ended after accrual completion; the database lock was Dec 31, 2019. FINDINGS: Between March 30, 2015, and Aug 3, 2018, 79 patients were enrolled. 75 patients were assessable. 319 (71%) of the 450 planned courses were delivered. At 1 year from enrolment the primary endpoint was met, 42 patients were progression free (progression-free survival 58%; 95% CI 55-61). 49 patients (65%; 95% CI 54-76) had an objective response after MATRix-RICE, 29 (39%) of whom had a complete response. 37 patients who responded had autologous HSCT. At the end of the programme, 46 patients (61%; 95% CI 51-71) had an objective response, with a median duration of objective response of 26 months (IQR 16-37). At a median follow-up of 29 months (IQR 20-40), 35 patients were progression-free and 33 were alive, with a 2-year overall survival of 46% (95% CI 39-53). Grade 3-4 toxicity was most commonly haematological: neutropenia in 46 (61%) of 75 patients, thrombocytopenia in 45 (60%), and anaemia in 26 (35%). 79 serious adverse events were recorded in 42 (56%) patients; four (5%) of those 79 were lethal due to sepsis caused by Gram-negative bacteria (treatment-related mortality 5%; 95% CI 0·07-9·93). INTERPRETATION: MATRix-RICE plus autologous HSCT was active in this population of patients with very poor prognosis, and had an acceptable toxicity profile. FUNDING: Stand Up To Cancer Campaign for Cancer Research UK, the Swiss Cancer Research foundation, and the Swiss Cancer League.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Ferreri AJM, Doorduijn JK, Re A, et al. MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematol. 2021. PMID: 33513372. doi:10.1016/S2352-3026(20)30366-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。